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A 56-year-old male was presented to our medical center after
a suicide attempt. His past medical history was significant for
type 2 diabetes requiring insulin, depression treated with
paroxetine, and previous intravenous drug abuse on
methadone maintenance. On the night before admission he
had ingested an unknown quantity of 400 mg tablets of
quetiapine and 90 mg of methadone. On the way to the
hospital, he was given naloxone 0.4 mg and intravenous
fluids. At presentation to the hospital, he was afebrile, with
blood pressure 96/56 mm Hg, heart rate of 110 per min, and
respiratory rate of 40 per min. On physical examination, he
was drowsy with dilated pupils, clear lungs, regular heart
sounds without murmurs, and decreased bowel sounds. His
labs revealed serum sodium 119 mequiv./l, chloride 70 me-
quiv./l, potassium 3.8 mequiv./l, bicarbonate 28 mequiv./l,
calcium 8.2 mg/100 ml, phosphorus 3.7 mequiv./l (subse-
quently 1.7 mequiv./l), blood urea nitrogen 64 mg/100 ml,
and creatinine of 1.8 mg/100 ml (up from 0.8 mg/100 ml the
week prior). His anion gap was calculated at 23.5. His arterial
blood gas revealed a pH of 7.86, a PCO2 of 14 mm Hg and
PO2 178 mm Hg.
His urinary studies revealed a pH of 5.0, protein 30 mg/
100 ml, trace blood, 2–5 red blood cells/HPF, 2–5 white blood
cells/HPF, and 2–5 granular casts. Additional studies included
a urinary sodium o10 mmol/l, chloride o10 mmol/l,
creatinine 97 mmol/l, and osmolality 526 mmol/l. He had a
negative toxicology screen for paraldehyde, methanol,
ethanol, ethylene glycol, salicylates, propylene glycol, and
ketones. His lactate was mildly elevated at 2.1 mmol/l. He had
normal brain and chest imaging studies.
This patient has acute kidney injury likely from severe
volume depletion. He also has hypovolemic hyponatremia.
The most striking feature of his presentation was severe
alkalemia. His acid–base revealed a triple disorder of an anion
gap metabolic acidosis, metabolic alkalosis, and severe
respiratory alkalosis.
In this triple acid–base disorder,
what was the cause of his severe respiratory alkalosis?
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The Diagnosis | Respiratory alkalosis from quetiapine
Respiratory alkalosis can be induced by anxiety, cerebrovas-
cular disorders, salicylates, catecholamines, progesterone,
analeptic overdose, Gram-negative sepsis, endotoxemia,
hyperthyroidism, hypoxia, liver insufficiency, pulmonary
edema or pulmonary embolism, and early restrictive lung
disorders.1 In our patient, all these causes were considered
and ruled out. Once cerebral edema from acute hypona-
tremia was ruled out as a cause of the respiratory alkalosis
with a normal head computerized tomography scan, the
quietapine itself was thought to be the primary culprit in his
respiratory alkalosis. Clinical trials of quietapine and more
recently, a case report2 published have reported hyperventila-
tion associated with this drug. Quetiapine is a novel
dibenzothiazepine atypical antipsychotic with higher affinity
for the serotonin 5-HT2 receptors than for dopamine D2
receptors. Clinical trials of quetiapine reported hyperventila-
tion as a rare adverse effect (o1/1000 patients), although
causality was not established.2 The proposed mechanism for
a drug-induced hyperventilation is a direct action on the
respiratory center in the brain stem and stimulation of either
peripheral or central chemoreceptors, as well as modulation
of central neurotransmitters such as serotonin.2 The
concomitant ingestion of a selective serotonin reuptake
inhibitor (paroxetine, in this case) may have worsened the
hyperventilation.2
This patient had a severe alkalemia as a result of coexisting
metabolic and respiratory alkaloses.
The metabolic component was likely due to severe
vomiting resulting in a chloride responsive contraction
alkalosis. The etiology of his anion gap metabolic acidosis
is multifactorial. Severe alkalemia can cause an increase in
anion gap.3 Alkalemia also causes glycolysis in the liver and a
mild lactic acidosis (seen in our patient).3 In addition, in a
volume contracted patient like ours, the remaining change in
anion gap can be due to the change in valence of circulating
proteins to preserve extracellular volume.4
Our patient had mild hypokalemia and his ionized
calcium was low at 0.79 mmol/l, but no significant electro-
cardiographic changes and no events on telemetry were
noted. His phosphorus level was normal on admission but
precipitously dropped to 1.7 mequiv./100 ml within hours, a
phenomenon frequently seen with a respiratory alkalosis.1
The patient was aggressively resuscitated with 8–10 liters of
0.9% normal saline and his acute renal failure, hyponatremia,
and acid–base disorders completely resolved within 48 h.
This case highlights a severe combined respiratory and
metabolic alkalosis, the cause of hyperventilation being
quetiapine. We recommend monitoring the respiratory status
in patients following the initiation and titration of this drug,
especially the patients with severe anxiety disorders, and in
individuals taking medications that inhibit CYP3A4 meta-
bolic pathway and increase serotonin levels.2
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